NORCROSS, GA -- (Marketwired) -- 10/06/15 --
Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announced today that Executive Chairman Jim Czirr will be interviewed on "The Big Biz Show" hosted by Bob "Sully" Sullivan. In this exclusive interview, Mr. Czirr will discuss Galectin Therapeutics' progress developing a treatment for the silent epidemic Fatty Liver disease and advanced liver fibrosis and cirrhosis. Listeners will also hear about results that occurred in the most recent clinical trials.
Date: Tuesday, October 6, 2015
Start Time: 3:00pm ET | 12:00pm PT | 2:00pm CT (U.S.)
Network: Syndicated: AFN, TiVo, CBS Radio, Fox Business, AOL, YouTube, Biz Talk Radio, Clear Channel
Show: The Big Biz Show
Host: Bob "Sully" Sullivan
TV Stream: http://www.ustream.tv/biztv
About The Big Biz Show
The Big Biz Show is a nationally syndicated radio / television program broadcast on 150 stations throughout the country with a weekly reach of 1.7 million listeners reaching over 70 million homes. The Emmy Award-winning show was named by TALKERS Magazine as one of the "Top 10 Most Influential Financial Shows" in the country, and is highly recognized for discussing current business events, internet related issues, and other hot topics in the business world, doing so in an informing, laid back, and humorous manner. Hosts, Bob "Sully" Sullivan and Russ "T Nailz" Stolnack, both are renowned and experienced radio broadcast personalities. The Big Biz Show airs Tuesday through Friday, 12:00 p.m. to 1:00 p.m. PT.
About Jim Czirr
Jim Czirr is the Executive Chairman of Galectin Therapeutics, the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer. Mr. Czirr is a co-founder of 10X Fund, L.P. and is a managing member of 10X Capital Management LLC, the general partner of 10X Fund, L.P. Mr. Czirr was a co-founder of Galectin Therapeutics in July 2000. Mr. Czirr was instrumental in the early stage development of Safe Science Inc., a developer of anticancer drugs. He served from 2005 to 2008 as Chief Executive Officer of Minerva Biotechnologies Corporation, a developer of nano particle bio chips to determine the
cause of solid tumors, and was a consultant to Metalline Mining Company Inc., now known as Silver Bull Resources, Inc., (OTCQB: SVBL), a mineral exploration company seeking to become a low cost producer of zinc. Mr. Czirr received a B.B.A. degree from the University of Michigan.
About Galectin Therapeutics, Inc.
Galectin Therapeutics (NASDAQ: GALT), is a biotechnology company focused on discovery and development. We apply our leadership in galectin science and drug development to create new therapies for fibrotic disease and cancer. Drug candidates based on our unique carbohydrate technology target galectin proteins, which are key mediators of biologic and pathologic function. Galectin Therapeutics is pursuing therapies for indications in which galectins have a demonstrated role in the pathogenesis of a particular disease. We focus on diseases with serious, life-threatening consequences to patients, and those where current treatment options are limited. Our strategy is to establish clinical development approaches that add value to the Company in the shortest time possible,
and to seek partners as the program advances and requires much greater resources. Galectin Therapeutics leverages extensive scientific and development expertise as well as established relationships with outside sources to achieve cost effective and efficient development. We are pursuing a clear development pathway to clinical enhancement and commercialization for our lead compounds in liver fibrosis and cancer immunotherapy. To learn more about Galectin Therapeutics please visit us at http://galectintherapeutics.com
Company Contact:
Jim Czirr
Executive Chairman
Galectin Therapeutics, Inc.
4960 Peachtree Industrial Boulevard
Suite 240, Norcross, Georgia 30071
jimczirr52@gmail.com
http://galectintherapeutics.com
Interview / Media Contact:
Matthew BIRD
President
1-800-PublicRelations, Inc.
+1 (800) 872-6185
matt.bird@1800pr.com
www.1800pr.com
Source: Galectin Therapeutics
News Provided by Acquire Media
